While reporting financial results for the second quarter on Thursday, medical company Danaher Corp. (DHR) said it anticipates adjusted core revenue growth for the third quarter, including Cytiva, to be in the mid- to high-single digit range.
from RTT - Earnings https://ift.tt/3ePQx93
via IFTTT
No comments:
Post a Comment